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ABSTRACT
Objective: Guidelines for optimal follow-up for patients undergoing lower extremity
revascularization (LER) for peripheral arterial disease (PAD) recommend multiple visits with
imaging during the first year followed by yearly monitoring thereafter. Patients with chronic
limb-threatening ischemia (CLTI) are at greater risk for mortality and major amputation than
patients treated for claudication and thus necessitate closer monitoring. The goal of this paper is
to study the effects of compliance with follow-up after revascularization for patients with CLTI
on major amputation rates and mortality.
Methods: A single-center retrospective chart review of consecutive patients undergoing LER for
CLTI was performed. Patients were stratified based on compliance with follow-up to compliant
or non-compliant cohorts. Patient characteristics, reinterventions, and perioperative and longterm outcomes were compared between the two groups.
Results: There were 356 patients undergoing LER for CLTI and 61% (N=218) were compliant.
There was no significant difference in baseline characteristics between the two groups. Noncompliant patients were more likely to undergo endovascular interventions compared to
compliant patients (92.8% vs 79.4%, P=.03). There was no difference in perioperative outcomes
between the 2 groups with overall 30-day mortality of 0.6%. After mean follow up of 2.7 years,
compliant patients had greater ipsilateral reintervention rates (49.1% vs 34.1%, P=.005) as well
as overall reintervention rates (61% vs 44.2%, P= 0.002) compared to non-compliant patients.
There was no significant difference in mortality or ipsilateral major amputations between the 2
groups.
Conclusions: Patients who were compliant with follow-up after LER for CLTI underwent more
reinterventions with no difference in mortality or major amputation. Further research regarding
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the threshold for reintervention as well as the optimal schedule for follow up in patients with
CLTI is needed.
1. Introduction:
Peripheral artery disease (PAD) is a progressive disease that affects 8-10 million Americans over
40 years of age, and 12-20% of Americans above the age of 65. Additionally, there are 5001,000 per million new cases of critical limb-threatening ischemia (CLTI) every year.1-4 CLTI
occurs when PAD progresses to an advanced stage resulting in more severe symptoms, often
pain at rest or tissue loss, and is associated with worse outcomes. The presentation of CLTI
varies widely and outcomes depend on the availability and quality of primary and secondary
care. CLTI is associated with high morbidity and mortality with an estimated 12-month major
amputation rate of 22% in untreated individuals.5 Although CLTI represents the final stage of
PAD progression, approximately half of patients presenting with CLTI have no known prior
history of PAD.6,7 Successful management of CLTI begins with timely diagnosis and medical
management of relevant comorbidities. Growing evidence shows that optimizing medical
management of patients with PAD improves vessel patency and mortality.8-10 Next, lower
extremity revascularization (LER) is performed according to the anatomy and severity of
disease. Options for interventions are broadly categorized to either open surgery or endovascular
treatment (EVT). The number of techniques for treatment of CLTI with minimally invasive EVT
has increased in recent years and has led some to advocate an “endovascular-first” approach for
most patients with CLTI. However, evidence from ongoing trials argues for the use of selective
revascularization algorithms based on specific criteria.11-13 In practice, the frequency of EVT use
for treatment of PAD has increased dramatically and has surpassed that of open surgical
approaches.14-18
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It is generally accepted that achieving optimal outcomes after open surgical and
endovascular procedures requires clinical follow-up. All vascular procedures have modes of
failure that must be identified and managed in a timely manner. Optimal follow-up after LER
allows for the detection of recurrent disease and other complications at an early stage when they
can be managed safely and effectively even before clinical signs occur. Follow-up also offers the
opportunity to optimize pharmaceutical therapy, smoking cessation, pain management, and diet
and exercise. The Global Vascular Guidelines for management of CLTI recommend performing
a thorough interval history and a physical exam with complete examination of the foot including
assessment of neuropathy and a probe-to-bone test of any open ulcer in patients with tissue loss.
Furthermore, measurement of the ankle-brachial index (ABI) is recommended as the first-line
noninvasive test for diagnosis and surveillance of CLTI. Non-invasive arterial imaging is also
recommended at follow-up visits using typical duplex ultrasound (DUS) with the use of
computed tomography angiography (CTA), or magnetic resonance angiography (MRA)
selectively.
While significant strides have been made to improve endovascular tools and techniques,
data regarding post-operative management and follow-up protocol for patients with CLTI
remains debatable. The Society for Vascular Surgery currently recommends DUS surveillance
immediately after open lower extremity revascularization with continued follow-up at 3, 6, and
12 months and then every 6 to 12 months for life thereafter. As for endovascular therapies, the
optimal time for follow-up has yet to be determined with recommendations of follow-up varying
based on the clinical picture and severity of disease.19 The American College of Cardiology and
American Heart Association task force recommends periodic follow up for patients with CLTI to
monitor treatment response, symptom progression, and cardiovascular risk . However, the
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current guidelines for interventional cardiologists and interventional radiologists do not provide
an ideal follow-up timeline or protocol leaving the choice of timing and surveillance imaging
largely to the individual provider.20 Moreover, studies aiming to optimize follow-up for
endovascular treatments have yielded conflicting data putting in question the optimal method of
surveillance after LER.21-26 A recent study showed that patients who were lost to follow up at 1
year after undergoing endovascular intervention for PAD had worse long-term survival than
those whose records indicated a follow-up visit was performed during the first post-operative
year.21
Statement of Purpose:
This study focuses on the impact of compliance with a clinical follow up schedule for
patients with CLTI undergoing LER on reintervention, major amputation, and mortality. Our
hypothesis is that compliant patients have lower rates of major amputation and mortality
compared to non-compliant patients.
2. Materials and Methods:
Student Contributions: the electronic medical records of a total of 356 patients who underwent
LER for CLTI at Yale New Haven Hospital were reviewed by the writer and Alaa Mohamedali.
The information gathered was recorded into a RedCap database, a HIPAA compliant server.
After completion of data collection, the writer designed the study with the guidance of Dr.
Cassius Iyad Ochoa Chaar. Dr. Tanner Kim was also involved in the design of the study and
contributed as an advisor during the collection of data. Statistical analysis was performed by
Haoran Zhuo with supervision and consultation of Dr. Yawei Zhang.
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Ethics Statement: This thesis includes a retrospective cohort study that was done to better
understand the impact of follow-up after LER for CLTI patients on the outcomes of
revascularization. No live human subjects were harmed in the making of this thesis and private
health information was carefully used according to the guidelines of the Health Insurance
Portability and Accountability Act of 1996 (HIPAA). The use of the word “compliance” in this
study strictly refers to the adherence to a protocol of follow-up and is not meant to pass judgment
or place blame on patients.
Human Subjects Research: This study was approved by the Yale University Institutional
Review Board, and no patient consent was required.
2.1. Study Design
A retrospective review of the electronic medical records (EMR) of consecutive patients
diagnosed with CLTI undergoing open or endovascular LER at Yale New Haven Hospitals by
multiple providers from different specialties (vascular surgery, interventional cardiology, and
interventional radiology) was performed. Patients with no records in the EMR after LER or who
died within 3 months of the index procedure were excluded from this analysis. Patients were
stratified according to their compliance with clinical follow-up into compliant and non-compliant
groups: stratification was done at the time of data collection and entry into the database. Followup compliance after revascularization was defined as in-person follow-up visits with any
vascular specialist addressing the perfusion status of the limb at least once during the first 3
months, and a second time in the following period of up to 15 months after the index procedure.
Even though more frequent follow up, initially, and yearly lifetime visits have been advocated,
these 2 visits were considered a minimal threshold for patients to qualify as “compliant”. These 2
visits also corroborate with the vascular quality initiative (VQI) guide for minimal compliance
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with long-term follow up that provides a window of 9 to 21 months to record follow up.27 Any
patient who did not meet the criteria was considered non-compliant with follow-up. It is
important to note that compliance in this study strictly refers to adherence to the clinical visit
schedule. For example, patient that comes for their first follow-up visit more than 3 months after
the index procedure is considered non-compliant even if they continue to follow-up with a
clinician for years after the procedure. Furthermore, total follow-up time of an individual patient
was calculated as the time from the index procedure until the last recorded clinical visit in the
EMR. Post-operative adherence to best medical therapy, diet, exercise, smoking cessation, and
surveillance imaging were not recorded in this study. Follow up with primary care physicians or
other specialists that do not address the status of limb perfusion did not count towards
compliance but allowed the capture of information related to symptoms, major amputation, and
mortality. Patients that were admitted to the hospital and received follow up as inpatient only
without an outpatient visit with a vascular specialist after discharge were considered noncompliant. Compliance with follow up was analyzed based on the first LER procedure in patients
who underwent additional reinterventions.
2.2. Patient characteristics:
Patient characteristics were individually reviewed, and data collected included patient
age, gender, race, comorbidities, and medications (aspirin, ADP/P2Y12 inhibitor,
anticoagulation medications, and statins). Patient’s history of current or former smoking,
diabetes, chronic renal insufficiency (CRI) defined as baseline creatinine above 1.5 mg/dL or a
glomerular filtration rate of less than 60 mL/min, serum creatinine, end stage renal disease
(ESRD) requiring dialysis, hypertension, hyperlipidemia, coronary artery disease (CAD),
congestive heart failure (CHF), stroke, hypercoagulable disease, history of cancer, and history of
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prior endovascular procedures or prior open procedures for LER were noted. All patient
characteristics were recorded as of the index procedure. Changes to patient characteristics after
the index procedure were not recorded.
2.3. Procedures
The first intervention in the EMR during the study period was captured and considered
the index procedure to assess compliance. Patients with records indicating interventions dating
prior to the establishment of EMR were carefully reviewed and any data available from pre-EMR
records pertaining to revascularization was recorded whether from manually inserted old records
or physician notes. Reinterventions were individually recorded in the database. The date of the
procedure, performing physician, indication (rest pain or tissue loss), and anatomical level was
captured. Procedure types were divided into either endovascular, open, or hybrid. Endovascular
therapies consisted of balloon angioplasty, stenting, and atherectomy. Open procedures were
divided into suprainguinal bypass, infrainguinal bypass or endarterectomy, typically of the
common femoral artery. Hybrid procedures included a combination of open and endovascular
LER.
2.4. Perioperative Outcomes
Complications within 30 days of the intervention were individually reviewed. The
following procedural complications were recorded: hematoma, pseudoaneurysm, bleeding,
wound infection, pneumonia, urinary tract infection, arterial thrombosis, deep vein thrombosis,
stroke, acute renal failure, acute need for hemodialysis, unplanned return to the operation room
within 30 days, major amputation, and death. Bleeding was defined as any transfusion

11

requirement or return to the operating room due to bleeding. Major amputation was defined as
any amputation at or above the ankle.
2.5. Long-term Outcomes
Long-term follow-up outcomes were collected. Mean follow-up time in years for each
study group was derived. The frequency of overall reinterventions as well as ipsilateral
reinterventions were calculated. Reintervention rate was defined as the percentage of patients
undergoing any other LER after the index procedure. The reintervention index was defined by
the number of reinterventions recorded for patients divided by the years of follow up.28 Longterm major amputation ipsilateral to the index limb treated and mortality were captured. Patients
who had index procedures on bilateral limbs were considered to have an ipsilateral reintervention
or major amputation if it occurred on either limb. Additionally, mortality was also recorded using
the electronic medical record or social security death index.
2.6. Statistical Analysis
Continuous data was reported as mean ± standard deviation. Categorical data was
reported as percentages. P <0.05 was considered statistically significant. Differences between
the two cohorts were compared using Chi-Square test for categorical variable and student t-test
for continuous variables. Multivariable regression was performed to determine the factors
associated with survival, ipsilateral reintervention, and major amputation. These factors included
smoking, age, BMI, compliance with follow-up, diabetes, ESRD, CHF, and CAD.

3. Results
3.1. Patient Characteristics
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There were 356 patients that underwent LER for CLTI. There were 218 (61.2%) patients
who were compliant with follow-up. There were no significant differences in demographics,
comorbidities, or medical management between patients who were compliant with follow-up and
those who were not. (Table I)
3.2. Procedures
There were 61 index procedures for rest pain and 295 for tissue loss with no significant
difference in indication between the 2 groups. Patients in the non-compliant group were more
likely to have undergone an endovascular procedure compared to compliant patients (92.8% vs
79.4%, P=0.003). Also, patients in the compliant group were more likely to undergo
infrainguinal bypass (13.3% vs 5.8%, P=.024) and common femoral endarterectomy (8.7% vs
2.2%, P=.013) compared to the patients in the non-compliant group. (Table II)
3.3. Perioperative Outcomes
There was no significant difference in the perioperative (30-day) outcomes observed
between patients who were compliant with follow-up and those who were not. More specifically
the overall rate of perioperative major amputation, any morbidity, and mortality were 3.6%,
25.3%, and 0.5% with no differences between the groups. (Table III)
3.4. Long-term Outcomes
The mean follow-up time was 2.7 ± 1.8 years with no significant difference between the
2 groups (P=0.202). Overall, 49.1% of compliant patients received an ipsilateral reintervention
compared to only 34.1% of non-compliant patients (P=0.005). The average number of ipsilateral
reinterventions in compliant patients was significantly higher at 2.2 ± 1.8 compared to 1.60 ± 1.1
in the non-compliant cohort (P=0.02). However, the reintervention index, after adjusting for time
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of follow up, was not statistically significant (P= 0.419). Patients compliant with follow-up had a
significantly higher overall reintervention rate compared to patients non-compliant with follow
up (61% vs 44.2%, P=.002) and had more frequent overall mean number of reinterventions (2.7
± 2.3 vs 2.1 ± 1.7, P=.036). There was a trend towards a higher reintervention index in noncompliant patients that did not reach statistical significance (1.8 ± 2.2 vs 1.2 ± 2.4, P=.094).
There was no difference in mortality or major amputation between the 2 groups. (Table IV)
3.5. Risk Factors Associated with Ipsilateral Reintervention
Multivariable regression analysis was performed to examine the independent association
of individual variables with ipsilateral reintervention during the study period. Increased age was
associated with a decrease in the odds ratio of receiving ipsilateral reintervention (OR= 0.98
[0.96-1.00]). Compliance with follow-up was associated with significantly increased likelihood
of receiving ipsilateral reintervention (OR= 1.82 [1.15-2.89]). Moreover, patients undergoing
open, or hybrid procedures were found to have significantly decreased likelihood of receiving a
reintervention (OR= 0.48 [0.27, 0.83]). (Table V)
3.6. Risk Factors Associated with Ipsilateral Major Amputation
Multivariable regression analysis was performed to examine the independent association
of individual variables with major amputation of the ipsilateral index limb. Patients with ESRD
had an increased odds ratio for ipsilateral amputation (OR= 4.16, CI [1.95-8.86]), while CHF
was associated with decreased odds ratio for ipsilateral amputation (OR= 0.36 [0.14-0.95]).
Furthermore, patients undergoing open, or hybrid procedures had a significantly increased
likelihood of ipsilateral major amputation (OR= 2.59 [1.17, 5.77]). Notably, compliance with
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follow-up showed no statistically significant association with receiving ipsilateral amputation in
this analysis (P= 0.183). (Table V)
3.7. Risk Factors Associated with Mortality
Multivariable regression analysis was performed to examine the independent association
of individual variables with mortality. Procedure modality did not show an association with
mortality on regression analysis. Increasing age (OR= 1.05 [1.02-1.07]) and ESRD (OR=4.88
[2.38, 10.01]) were the only factors noted to be independently associated with increased
mortality. Compliance with follow-up had no significant association with mortality (P= 0.179).
(Table V)
4. Discussion
Clinical follow up is an essential element in the optimization of outcomes of patients after
any vascular procedure. The role of follow-up is widely accepted in the medical community yet
the data surrounding the effects of clinical follow-up on outcomes have not been consistently
reported in the literature. In this study, patients who were compliant with the proposed follow-up
schedule after LER for CLTI were found to have higher reintervention rates following the index
procedure with no difference in mortality or major amputation rates. Compliant patients were
more likely to have had open bypass procedures than patients who were non-compliant with
follow-up. On regression analysis, open and hybrid procedures were associated with decreased
reintervention. However, there was no association between compliance with follow up and the
outcomes of major amputation and mortality. These findings raise the important question of
whether compliance with follow-up yields better outcomes, and whether the current thresholds
for reintervention and paradigms for follow up are optimal.
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The current guidelines published by the Society for Vascular Surgery (SVS) confirm that
there is still a pressing need for better clinical data on all aspects of follow-up after vascular
surgery procedures.19 Particularly, there is a need for data surrounding indications for
reintervention, as well as duration, frequency, and modality of surveillance. Modalities for
surveillance include clinical follow-up visits for symptom assessment by physical exam, ABI
measurements, and DUS scan. Other imaging modalities such as digital subtraction angiography,
CTA, and MRA are not recommended due to the higher cost, limited access, as well as the
associated contrast dye and radiation exposure risks and should be used selectively.29
Currently, SVS guidelines strongly recommend clinical examination and ABI, with or
without DUS in the early postoperative period after aortobifemoral, iliofemoral, femoralfemoral, and axillobifemoral bypass to provide a baseline for further follow-up. Afterwards,
evaluation should be repeated at 6 and 12 months and then annually as long as patients are
asymptomatic.19 Patients with prosthetic infrainguinal bypass grafts should receive the same
surveillance. DUS should be added to the surveillance regimen in patients who undergo
infrainguinal vein graft bypass. Furthermore, an increased frequency of surveillance during the
first postoperative year is recommended for these patients with evaluations in the perioperative
period, and at 3, 6, and 12 months and at least annually thereafter. It is important to note that
while these are strong recommendations, they are primarily based on low to moderate quality
evidence.19
As for endovascular treatment (EVT), SVS guidelines also strongly recommend clinical
examination, ABI, and DUS within the first month after aortoiliac segment EVT to provide a
baseline and to evaluate for residual stenosis. Clinical examination and ABI with or without the
addition of DUS should be performed at 6 and12 months and then annually as long as there are
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no new signs or symptoms. A more frequent schedule is also suggested for EVT of the
femoropopliteal and tibial segments with evaluations at 1, 3, and 6 months followed by
evaluations every 6 months thereafter. To understand the rationale for these recommendations, it
is appropriate to highlight some of the current literature on the outcomes of open and
endovascular LER for CLTI, followed by available evidence for the frequency, duration, and
modalities used for postoperative surveillance.
Outcomes of CLTI after Open Bypass:
The outcomes of CLTI after open bypass surgery has been extensively reported in the
literature. However, quality studies reporting details regarding surveillance are scarce. Bypass
surgery and endarterectomy have been performed for the treatment of CLTI and the outcomes of
these procedures vary by anatomic location and bypass graft used. Aortobifemoral bypass
patency rates are excellent and in the range of 88% to 93% at 3 to 5 years.30,31 Iliofemoral bypass
performed for unilateral iliac artery occlusive disease is performed as an alternative to femoralfemoral bypass to avoid bilateral groin incisions. Studies reporting long term follow-up
outcomes list primary patency ranges of 61% to 66% at 5 to 8 years.32,33 While secondary
patency rates were as high as 80% to 93% at 5 years.33,34 Femoral-femoral bypass can be
performed for unilateral iliac artery disease and generally results in patency rates lower than
those of aortobifemoral bypass. One prospective study reports a 5-year primary patency rate for
this technique as 35% although details of surveillance methods were not clearly described.35
Another study used DUS criteria to guide reinterventions in patients who had received femoralfemoral bypass saw an increase in 5-year primary patency and primary-assisted patency rate
from 62% to 88%.36 Axillobifemoral bypass is a technique performed in patients who cannot
receive aortic reconstruction or those with a history of aortic graft infection. The SVS reports on
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the paucity of literature addressing surveillance of this procedure. Cumulative patency rates of
85% to 87% at 3 to 4 years are reported with no details regarding surveillance modality or
frequency.37,38 Infrainguinal revascularization with vein graft is one of the most common
procedures for CLTI LER.19 There are multiple modes of failure and complications as well as
timelines for these failures. The bypass is at risk of early, midterm, or late failure. Early failure
(within 30 days is generally due to technical issues during surgery. Midterm failure (30 days to 2
years) may be due to intimal hyperplasia affecting the conduit or anastomosis. Late failures (after
2 years) often occur as a result of atherosclerosis progression affecting the inflow and/or outflow
vessels.39
Outcomes after EVT:
With the constant development of endovascular and minimally invasive devices, EVT has
been an attractive option for treatment of CLTI. Options for EVT treatment include plain balloon
angioplasty, stenting (bare metal, covered, and drug-eluting), and atherectomy. Several studies
have reported on the long-term outcomes and natural history of CLTI after EVT. The most
important complication for EVT of CLTI is restenosis. The specific pathophysiology involved in
restenosis is not yet fully understood. However, it is largely believed that inflammation due to
injury to arterial smooth muscle cells, endothelium, and thrombus deposition plays a key role in
restenosis after EVT.40 Moreover, one study examining this phenomenon explains that restenosis
may occur as arterial remodeling and/or neointimal hyperplasia.41 These authors observed that
restenosis after balloon injury was due to a combination of arterial remodeling and neointimal
hyperplasia, while restenosis after stenting consisted mostly of neointimal hyperplasia.
Furthermore, the neointimal hyperplasia was observed to be more significant in the stent group
when compared with the balloon group.
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Midterm and long-term outcomes for EVT of aortoiliac disease have been excellent. 5year primary patency rates were reported to be 64% to 82%.42-44 A large retrospective study
reported primary patency of aortoiliac stenting in 2096 patients to be 93%, 83%, and 78% at 1
year, 3 years, and 5 years, respectively. 45 As in the case of open procedures, reports of DUS
surveillance after aortoiliac EVT are rare in the literature. One such study reported 72 cases of
iliac artery balloon angioplasty which were surveyed by DUS at 1 month, 3, months, and 1
year.46 Results of the study showed that patients with DUS determined residual stenosis or
restenosis were not significantly different from those with normal findings on DUS.
Femoropopliteal segments are commonly treated by EVT. One study examining
outcomes of patients receiving femoropopliteal EVT for CLTI reported primary and secondary
patency rates of 41% and 79%, respectively.47 A retrospective study reviewing 330 cases of
superficial femoral artery stenting monitored by DUS derived criteria to help determine which
patients have significant restenosis.48 The authors concluded that the peak systolic velocity
(PSV) and velocity ratio (Vr) measured by DUS correlate with in-stent restenosis and may
predict it with high specificity. The VIBRANT trial compared the long-term outcomes of
complex superficial femoral artery disease treated with covered Viabahn stents and those of
bare-metal nitinol stents.49 More than 30% of patients in both groups received at least on
reintervention. Primary patency rates at 3 years were similar and low for both at 24% and 26%,
respectively. However, bare metal stents had better primary-assisted patency than Viabahn stents
at 89% vs 70%, P= 0.04, and similar secondary patency 89% vs 80%, P=0.304. The authors
concluded that patients who have received complex femoropopliteal stenting would benefit from
a rigorous surveillance program, particularly during the first postoperative year. This is due to
the rapid decline of patency rates observed during the first year of device implantation. In-stent
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restenosis poses a significant challenge in the management of CLTI in femoropopliteal segments.
A study by Armstrong et al observing patients receiving EVT for femoropopliteal in-stent
restenosis (ISR) reported that the angiographic characteristics of femoropopliteal ISR were
significantly associated with long-term outcomes. Moreover, patients with CLTI had
significantly worse outcomes than patients with claudication. After 2 years of follow-up, patients
treated with EVT for total occlusion of stents (Class III ISR) had the highest risk of recurrent
ISR (HR 2.4, 95% CI 1.1–5.6) and recurrent occlusion (HR 5.8, 95% CI 1.8–19.0) compared to
other types of ISR.
EVT for tibial revascularization is almost exclusively used in cases of CLTI.19 It has been
proven that tibial segment EVT is effective in significantly reducing major amputation rates in
CLTI. In study describing 417 diabetic CLTI patients with ischemic foot ulcers undergoing
lower-limb subtraction angiography, 63% of cases had diffuse lesions with occlusion of 3
arteries and multiple stenoses of the tibioperoneal and/or femoropopliteal segment.50 Because
most cases of tibial revascularization reported in the literature included treatment of lesions
extending towards the proximal femoral and popliteal segments, an accurate evaluation of tibial
revascularization outcomes is challenging. In a report focusing purely on tibial segments, limb
salvage at 3-5 year follow-up was 72-98% and average primary patency was reported at 55% at
6-24 months.51 Saqib et al examined the outcomes and predictors of restenosis for EVT of the
tibial arteries.52 DUS surveillance was used to determine restenosis. In patients with worsening
wounds, angiography was used regardless of DUS findings. Tibial artery restenosis or occlusion
was observed in 41% of limbs. Restenosis or occlusion significantly increased the risk of major
amputation (27% vs 4%). Furthermore, the need for further reintervention for patients receiving
repeated EVT was observed to be higher than those who received open bypass reintervention.
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Additionally, studies have compared the outcomes of different EVT and open bypass
techniques on the treatment of PAD. One such was a meta-analysis conducted by Almasri et al in
2018 evaluating relevant outcomes of infrainguinal revascularization procedures in patients with
CLTI. They found that patency rates are highest for saphenous vein bypass, whereas both
patency and limb salvage are markedly inferior for prosthetic grafting of below the knee
segments. Among endovascular interventions, percutaneous transluminal angioplasty and drugeluting stents appear comparable for focal infrapopliteal disease. The authors state, however, that
heterogeneity in patient risk, severity of limb disease, and anatomy renders any comparison
difficult to make from a retrospective study. The BASIL trial was a multi-center randomized
controlled trial wherein 452 patients with CLTI were randomized to either balloon angioplasty
(n= 228) treatment or bypass surgery (n= 224) for treatment of infrainguinal disease.53 All
patients were followed for at least 3 years. Results showed that patients randomized to balloon
angioplasty had higher immediate technical failure than those receiving bypass surgery (20% vs
2.6%; P= 0.01). Outcomes of vein bypass grafts were better than prosthetic grafts for
amputation-free survival (P= 0.003) but not for overall survival (P= 0.38). The authors also
found that patients who received bypass surgery after failed balloon angioplasty had significantly
worse survival than those who received bypass surgery as a first revascularization. However, the
trial also noted that balloon angioplasty appeared overall superior to prosthetic graft bypass
surgery. The authors of the BASIL trial published a clinical tool to predict the survival of
patients with CLTI based on patient characteristics which may be used when deciding on a
treatment and surveillance modality.54
ABI utility in CLTI:
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The ABI is a measurement that provides objective data that serves as the first-line
modality for the diagnosis of lower extremity PAD. It is a relatively simple and cost-effective
tool that offers prognostic data that are useful to predict limb survival, wound healing, and
patient survival. The ABI can be used in initial diagnostics of disease but also as a surveillance
tool to monitor the efficacy of therapeutic interventions.55 An abnormal ABI value may offer the
physician useful information when assessing the risk of a patient for disease progression. For
example, one study reports that patients with an ABI value less than 0.40 are more likely to
experience rest pain, and hence, progression to CLTI.56 Conversely, an ABI value greater than
0.50 suggests that progression to CLTI is unlikely during the subsequent 6.5 years.57 However,
ABI values exceeding 1.40 were reported to carry a higher hazard of cardiovascular related
mortality.58 Indeed, the relationship between the ABI and atherosclerosis risk factors has been
confirmed, as well as the link between abnormal ABI and cardiovascular and cerebrovascular
disease.59 In a study which included 1537 elderly men and women, low ABI was predictive of
total and cardiovascular mortality with an increased relative risk of up to 4-fold.60
Lijmer et al used a receiver operating characteristic (ROC) analysis to determine the
diagnostic accuracy of ABI in patients with femoropopliteal and infrapopliteal disease. The
authors concluded that ABI had a sensitivity of 79% and specificity of 96% to detect stenoses of
50% or more reduction in the arterial lumen diameter.61 Another study using similar parameters
showed that the ABI had a sensitivity of 95% and a specificity of 100% compared with
angiography.62 Moreover, Feigelson et al measured a sensitivity and specificity of 89% and
99%.63 The same study also reported a positive predictive value of 90%, and a negative
predictive value of 99% with an overall accuracy of 98%. Despite the variation in reported
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sensitivity values across different studies, the utility and overall accuracy of ABI measurements
as a diagnostic tool for PAD has been well-established.
In a study by Ouriel and Zarins, the authors demonstrate that ABI may provide better
discrimination than the absolute ankle pressure alone when comparing between normal lower
limb arteries and those with PAD. However, neither ABI nor absolute ankle pressures can
reliably differentiate between normal limbs and asymptomatic limbs that have arteriographically
confirmed PAD. The authors explain that this may be because early stenotic changes can be mild
and hemodynamically insignificant before becoming symptomatic.64 This phenomenon is
important when considering the utility of ABI in the postoperative surveillance of CLTI.
McLafferty et al. conducted a study to determine if changes in the value of ABI correlated with
progression of disease after open LER during a mean follow-up of 3.3 years. Using arteriography
and DUS as standard, ABI had a sensitivity of 41%, specificity of 84%, positive predictive value
of 59%, and an accuracy of 68% for detecting progression of disease.65 Considering the costeffectiveness and non-invasive nature of ABI measurements, these results suggest a role for ABI
in monitoring disease progression after LER. Confirming the accuracy of abnormal ABI
measurements with other imaging modalities such as DUS or arteriography would be reasonable.
It is important to note, that there are limitations to ABI measurements alone. Patients may
have severely stenotic or totally occluded iliofemoral arteries yet exhibit a normal ABI at rest
with adequate compensation from collaterals. Because the ABI relies on arteries being
compressible for an accurate reading, extensive atherosclerosis rendering an artery noncompressible may artifactually increase the ABI value. Therefore, the presence of a normal or
high ABI in patients with symptoms strongly suggesting arterial disease should receive
additional testing to rule out CLTI. Alternative tests such as toe-brachial pressure, doppler
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waveform analysis, pulse volume recording, exercise ABI test, or DUS may be used.55 Saarinen
et al compared patients monitored by ABI, toe pressures and DUS after EVT. ABI and toe
pressures missed approximately 30% of lesions detected by DUS in post-EVT arteries.23 The
authors go on to explain how this discrepancy in lesion detection may cause unnecessary delay in
repeat interventions for these patients. In fact, one study noted that a significant decrease in ABI,
defined as >0.15 may not be present until a >60% stenosis exists.48 This problem is particularly
crucial in diabetic patients where ulcer healing time is longer and undetected stenosis may
prolong that healing even more.
DUS utility in CLTI
DUS After Open Bypass:
A randomized controlled trial evaluated the effect of adding DUS to a surveillance
protocol that included clinical examination and ABI after infrainguinal vein graft
revascularization.66 179 patients undergoing infrainguinal vein graft revascularization during a 3year period were scheduled for surveillance at 1, 3, 6, 9, and 12 months after operation. The
authors compared the rate of reinterventions, overall cumulative assisted primary patency and
secondary patency, and limb salvage. However, the study failed to show any beneficial effect of
DUS in a surveillance program.
Lundell et al showed in an experimental study that patients who received a
femoropopliteal graft had significantly better assisted-primary and secondary vein graft patency
if they followed an intensive surveillance regimen as opposed to the routine surveillance
protocol. The intensive surveillance regimen included clinical examination, ankle/brachial index
measurements, and DUS scans every 3 months for the first 2 years, and yearly after operation. If
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DUS scans showed stenosis, angiography was performed. If angiography showed stenosis, a
revision (surgical or endovascular resulting in comparable outcomes) was performed. Routine
surveillance was clinical examination and ankle/brachial index measurements without duplex
scanning at 1, 12, 24, and 36 months after operation.67 Angiography was performed for the
routine surveillance group with recurrence of critical limb ischemia. Revisions were then
performed based on angiography findings. This study suggested that the intensity of the
surveillance program influenced outcomes, although it did not elaborate on compliance or the
role of DUS.
DUS After EVT:
One analysis of routine DUS after infrainguinal EVT questioned the utility of post-EVT
DUS surveillance.24 Consecutive patients undergoing EVT of the superficial femoral
artery (SFA) or popliteal artery were prospectively enrolled in a DUS protocol ≤1 week after
intervention, then at 3, 6, and 12 months thereafter. The authors found that the natural history of
arterial restenosis after EVT differs from that of vein graft bypass. The rate of thrombosis after
EVT despite normal findings on initial DUS was significantly higher than that for vein grafts.
After EVT, the tendency to develop restenosis was much greater, yet lesions appear more likely
to stabilize or regress compared to those found in autogenous vein grafts. Finally, 82% of
occlusions that occurred were in limbs in which only moderate, not severe, stenosis had been
detected. The authors conclude that the sensitivity of post-EVT DUS to predict occlusion was
88%. However, the specificity was only 60%. An estimated 40% of the limbs showing
restenosis on post-DUS EVT in this study would have gotten unnecessary interventions if DUS
criteria alone were used.
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A retrospective study conducted to evaluate whether DUS findings after infrainguinal
endovascular interventions for critical limb ischemia (CLI) were predictive of need for
reintervention or amputation over a period of 24 months.25 DUS was performed within one
month of the index procedure in 90 cases. 50 patients had an abnormal DUS result, and 40
patients had normal results. In patients with a normal duplex ultrasound the amputation rate was
5% vs 20% in the group with an abnormal duplex (P = .04). Primary patency was 56% in the
normal duplex group and 46% in the abnormal duplex group (P = .18). Importantly, early DUS
was able to identify residual stenosis not seen on completion angiography in 56% of cases. The
authors report that an abnormal DUS in the first 30 days after an intervention is associated with
an increased risk of amputation. They suggest a possible role for intraprocedural DUS, as well as
routine postprocedural DUS and close clinical follow-up in patients treated for CLI. Spijkerboer
et al conducted a study to determine if DUS one day after percutaneous transluminal angioplasty
(PTA) is prognostic for hemodynamic and clinical results at one year.26 34 femoropopliteal
artery segments treated with PTA received DUS imaging before PTA, one day after PTA, and
one year after PTA. The authors then report that all three arterial segments which showed
residual stenosis one day after PTA were occluded within one year. Clinical improvement was
also seen in most patients with DUS improvement one day after PTA, whereas results of DUS at
one year did not seem to correlate with hemodynamic or clinical status. Similarly, another study
examining the utility of DUS surveillance of the tibial arteries after EVT reported that DUS
surveillance did not significantly impact the outcomes of these patients.52 Another study showed
that the DUS criteria for restenosis of tibial arteries after prior EVT were reliable when
compared to angiography. However, the authors mentioned that limbs with detected stenosis
were only sent for repeat angiography if symptoms occurred.
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The current guidelines support duplex ultrasound surveillance and prophylactic
reintervention for asymptomatic vein graft stenosis to promote long-term patency. Guidelines for
reintervention after EVT have been left up to the discretion of the operator. Reports from the
literature vary in their thresholds for reintervention after EVT with most utilizing a mix of
angiographic findings of restenosis and clinical symptoms to determine the choice. There is a
paucity of high-grade evidence in the literature for the ideal indications for reintervention after
EVT.29 Hemodynamically significant restenosis as well as return of symptoms are the two main
causes for reintervention gleaned from the literature review. As mentioned previously, however,
the degree of restenosis required to observe clinical symptoms seems to vary. Regardless, it is
reasonable to say that postoperative imaging is a key component for optimal follow up to detect
disease before it becomes too severe.
A large study comparing the rate of postoperative imaging after LER between hospitals
showed that nearly half of older patients in the United States do not receive any type of followup imaging after LER.68 Indeed, the low rate of post-operative imaging was observed across the
United States with no appreciable difference in imaging rates based on the modality of
intervention, open versus endovascular. Therefore, despite the established guidelines for followup after LER with open surgery there still seems to be marked heterogeneity in the approach of
physicians to this matter. These findings highlight the importance of establishing standardized
and feasible guidelines for post-operative surveillance of CLTI. Furthermore, understanding the
barriers that hinder physicians and patients from complying with a standardized post-operative
imaging protocol is crucial.
A large retrospective study conducted by Wang et al recently reported that loss to followup at 1 year was associated with worse survival after open or endovascular LER for PAD.21 The
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aforementioned study supports the accepted belief that follow-up is critical to improving the long
term outcomes of patients receiving LER, but does not offer data that would help determine a
better follow-up regimen. Trials comparing surveillance frequency and modalities after EVT for
CLTI are still needed. It is not clear why the findings of our study differed from those of Wang et
al. One possible explanation is that our study utilized a different definition for follow-up
compliance. Wang et al considered patients who received in-person or telehealth follow-up once
during their first year post-operatively as compliant. Our definition of follow-up required inperson follow-up with a vascular specialist at a higher frequency. This also explains the much
higher follow-up rate of 91% in the mentioned study compared to our rate of 61%. A study by
Brooke et al reporting on in-person follow-up showed compliance rates closer to the ones we
report.68 In comparing outcomes of EVT and open bypass procedures for patients with CLTI,
Iida et al. reported a 44% 3-year reintervention rate in a multicenter study of 452 CLTI patients
who underwent revascularization by EVT or open surgery, comparable to the rates we observed
in our study.69 Moreover, our findings of factors associated with reintervention, major
amputation, and mortality were consistent with those published in the literature.70-73 It is possible
that the higher reintervention rates of follow-up compliant patients could be related to overly
aggressive reintervention thresholds. It is interesting to note that our regression analysis results
showed that open/hybrid procedures were independently associated with lower chances of
reintervention. Furthermore, the compliant with follow-up cohort had a significantly higher
proportion of patients undergo open/hybrid procedures. Despite the seemingly protective role of
the open/hybrid modality on reintervention rates, the compliant cohort still received a
significantly higher reintervention rate, which would mean that compliant patients in the
endovascular group must have received an exceedingly large number of reinterventions. Another
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possible explanation for the difference in reintervention rate is self-selection. While there were
no appreciable differences in the perioperative outcomes recorded for the two cohorts, it remains
entirely possible that patients who had recurrence of symptoms were more likely to return to the
clinic and have more reinterventions.
The association of individual variables with follow-up non-compliance was not examined
in this study as there were no differences in the preoperative characteristics of patients. However,
efforts to improve patient outcomes and optimize follow-up schedules must highlight known
factors that influence patient outcomes and follow-up compliance. The study conducted by Wang
et al showed that those who were lost to follow-up had important demographic differences
including a higher proportion of nonwhite race, diabetes, and urgent presentations.21 The
modality of follow-up also affected the long-term outcome of patients, with face-to-face followup having a more protective effect against mortality compared to phone follow-up. Face-to-face
follow-up was also found to be protective against mortality in a study evaluating the impact of
follow-up on EVAR patients.74 Patients who lived at home prior to admission showed lower
rates of loss to follow up than those who lived in nursing facilities, pointing to a possible adverse
effect of frailty on follow-up compliance.75 Female patients were less likely to be lost to followup, congruent with prior studies showing that males exhibited a higher no-show rate for
outpatient clinic appointments.76 Urgent presentation has also been shown to be associated with
increased mortality in a large National Surgical Quality Improvement Program study.78 Judelson
et al. conducted a study from a large national registry examining factors influencing loss to longterm follow up after vascular procedures. Multivariable analysis showed that center-specific
attributes were highly influential in impacting loss to follow up status.79 In fact, the authors note
that the effect size of the center was larger than the effects of all other factors combined. High
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performing centers likely have specific processes in places to increase compliance with followup. The authors of this study quantified the lack of documented long-term follow-up in this large
national registry and identified poor documentation as a key barrier to quality improvement.
Future efforts at improving follow-up should focus on studying the documented processes of
highly successful centers in follow-up compliance.
Guided by the review of literature conducted as well as the data gathered throughout this
thesis, a few recommendations for follow-up can be made. Follow-up for CLTI should be
decided based on the severity and anatomic location of the disease. All patients receiving LER
for CLTI should be monitored by clinical visits including ABI and/or toe pressure measurements.
A drop in the value of ABI of > 0.15 or recurrence of symptoms or change in pulse status should
prompt further imaging. Patients with CLTI may receive EVT or bypass surgery to treat their
disease. Due to the higher patency rates of revascularization in the aortoiliac segment, DUS
imaging is likely to be beneficial in the immediate perioperative period and once in the first
postoperative year if the patient remains asymptomatic. Patients who present with tissue loss
have demonstrated significantly worse outcomes than those who present with rest pain.80 Hence,
patients with tissue loss due to infrainguinal disease should be monitored carefully after
revascularization for tissue healing and be placed on a rigorous postoperative imaging
surveillance regimen with DUS in the immediate perioperative period, 1 month, 3 months, 6
months, and 12 months postoperatively followed by every 6 months. Due to the results of the
BASIL trial which revealed that CLTI patients receiving balloon angioplasty first for treatment
of infrainguinal disease prior to bypass had worse survival, all patients receiving EVT for
infrainguinal disease should be monitored with the same rigorous regimen described for tissue
loss. There was no evidence in our study that would prompt a change in follow-up
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recommendations for the societal guidelines of post-surgical bypass. The results of this study
revealed that patients receiving open surgery had a lower likelihood of reintervention. Bypass
surgery for patients with repeat occlusion after EVT may benefit this patient cohort more than
repeat EVT, especially if an appropriate vein graft is available. Moreover, patients with risk
factors such as end-stage renal disease, diabetes mellitus, and age > 75 years, should be carefully
surveyed as these risk factors carry the highest risk of poor outcomes. Furthermore, patients with
risk factors associated with loss to follow-up such as frailty, poor access to healthcare, or those
who do not live at home should be counseled on options for transportation and methods to ease
compliance with follow-up. Finally, any program of surveillance should carefully consider the
cost of imaging, the burden of travel for patients, as well as the risk of unnecessary
reintervention. Decisions to perform a reintervention on asymptomatic patients with recurrent
stenosis in the treated segment should be approached cautiously and patients should be counseled
appropriately on the consequences of restenosis and the risk of repeat occlusion.
The goal of treatment in CLTI is not only salvage of functional limbs, but also prevention
of cardiovascular risk factors to improve mortality. Constant monitoring and evaluation of
cardiovascular risk factors in all patients with CLTI is recommended by the Global Vascular
Guidelines for management of CLTI.29 Best medical therapy is critical and proven to improve
outcomes of patients with CLTI. The long-term use of antiplatelets for all patients with CLTI is
strongly recommended supported by high grade evidence coming from clinical trials showing
improvement in mortality, myocardial infarction, and stroke.81,82 While dual anti-platelet therapy
is recommended over single agent use in some cardiovascular pathology, a meta-analysis that
evaluating the use of ticagrelor, ticlopidine, aspirin, cilostazol, picotamide, vorapaxar, and
clopidogrel as single antiplatelet therapy versus dual antiplatelet therapy in patients with PAD
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found that clopidogrel monotherapy resulted in the best overall safety and efficacy.83 Lipidlowering agents, are also strongly recommended for all patients with CLTI, particularly those
with high cholesterol blood concentrations. A Cochrane review evaluated 18 trials including
10,049 patients reported that analysis showed lipid-lowering therapy significantly reduced the
risk of total cardiovascular events in PAD (OR, 0.74; CI, 0.55-0.98).84 It is well established that
control of blood pressure is crucial in the management of patients with cardiovascular disease.
One study showed that PAD patients had a significantly higher incidence of mortality from
cardiovascular events than those without PAD.85 Furthermore, PAD patients were less likely to
have cardiovascular events if their systolic blood pressure <145 mm Hg and diastolic pressures
<90 mm Hg. Further reduction of blood pressure to below 130 mm Hg systolic and 80 mm Hg
diastolic offered even greater protection from cardiovascular events. Therefore, control of
hypertension is an essential component of medical management of CLTI patients. Diabetes is
among the strongest risk factors for cardiovascular disease and PAD. Metformin is the first-line
therapy used for management of type 2 diabetes mellitus. Patients requiring additional agents
may be offered any of the other approved glucose lowering agents with equal effectiveness
according to one study.86 However, a large trial studying sodium-glucose co-transporter 2
(SGLT-2) inhibitors showed an approximate 2-fold increased risk of lower limb amputations
associated with the use of canagliflozin, an SGLT-2 inhibitor.87
Lifestyle modifications are also critical components of management of cardiovascular
disease, and CLTI patients may benefit greatly from adjustments such as smoking cessation, diet
improvement, and exercise programs. The harmful effect of tobacco use on cardiovascular health
is universally accepted. Patients who smoke should be encouraged to stop smoking at every
clinical visit and should be referred to smoking cessation programs if they are still smoking. Diet
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and exercise have not been specifically studied in CLTI. However, evidence in the literature
points to the benefit of healthy diet and exercise routines on progression of atherosclerotic
disease. Diets that reduce the intake of saturated fats and increases the intake of monounsaturated
fats, omega-3 fatty acids, antioxidants, and other natural plant sterols and stanols is associated
with a reduction in plaque burden and cardiovascular associated mortality.88-90 Further, numerous
trials have demonstrated benefits of a gradual supervised exercise routine in intermittent
claudication.91 Exercise rehabilitation has been shown to reduce the risk of recurrent myocardial
infarction and mortality.92 Although no trials for exercise rehabilitation have been done on CLTI
patients, it is reasonable to assume benefits for this patient cohort. Lastly, pain is a significant
stressor in the lives of patients with CLTI. Ischemic pain in CLTI patients is often complicated
by coexisting neuropathic pain, especially in diabetic patients. No trials have been reported for
optimal pain management in CLTI. Global Vascular Guidelines recommends a tiered approach
to pain management, balancing the benefits and harms of pain medications. Patients should be
offered acetaminophen with additional opioids based on the severity of pain. Laxatives and
antinausea medications may be prescribed for those who develop gastrointestinal side-effects of
opioids.29 Additional medications addressing neuropathic pain may also be prescribed in patients
already receiving high dose opioids with residual pain, especially in diabetic patients. These
medications include tricyclic anti-depressants, gabapentin, and pregabalin. However, care should
be taken to the associated cardiac risks of such medications.
Limitations:
Finally, this study has several limitations related to its retrospective design. The chart of
any patient that was found to be non-compliant with follow-up was carefully reviewed for any
evidence of follow-up visits with an outside provider by reviewing notes in the chart that may
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indicate outside follow-up. It is impossible to know with certainty whether some patients
followed with a vascular provider outside the system but kept follow up for other medical needs
within the system. That can potentially be captured as lack of compliance with the vascular
provider through the EMR review. However, this scenario should be limited to a very small
minority of the patients. Furthermore, the definition used in this study for compliance constitutes
the minimal recommended regimen of follow-up for a group of patients with predominantly
tissue loss. In practice, these patients require multiple visits during the first 1-2 months to ensure
wound healing, absence of infection and adequate revascularization. It is unclear whether an
alternative definition of compliance with a different frequency of follow up visits would have
affected the results of this study. During chart review, patients were recorded as compliant or
non-compliant based on the criteria of the study. The date of every individual visit which would
qualify as a clinical follow-up visit was not recorded nor were details of what occurred during
this follow-up. Testing of the impact of different follow-up schedules may have been possible if
these dates were recorded and would be a helpful element to consider in future studies of this
topic. Furthermore, self-selection bias from patients with recurrent symptoms may have
influenced the results of this study. Future studies examining the role of follow-up should
emphasize the clinical status of patients at each follow-up visit to control for this possible
confounder. Moreover, the lack of information regarding surveillance methods used during
follow-up visits prevents the passing of any judgment on the quality of follow-up for every
individual patient. Differences in post-operative adherence to best medical management,
smoking cessation, and proper wound care were not assessed in this study and could have
significantly impacted patients’ outcomes. Also, different thresholds for reintervention among
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different providers in the same specialty or across the various disciplines could have introduced
selection bias in some groups of patients and affected our results.
5. Conclusion
Compliant patients with follow up after LER for CLTI had higher reintervention
compared to non-compliant patients. However, there was no difference between the 2 groups in
major amputation or mortality. Prospective trials to define the optimal modalities of surveillance,
follow up frequency, and thresholds for reintervention after LER are needed.
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Table I: Characteristics of compliant and non-compliant patients with CLTI undergoing lower
extremity revascularization
Characteristics

Non-Compliant

Compliant

(N=138)

(N=218)

N(%)

N(%)

P

Demographics

Age (mean ± SD)

Male

69.8 ± 11.5

68.8 ± 12.8

0.467

89 (64.5)

125 (57.3)

0.179

Smoking Status

0.062

Former

53 (38.7)

109 (50)

Current

35 (25.6)

54 (24.8)

Nonsmoker

49 (35.8)

55 (25.2)

Race

0.952

White

93 (68.4)

146 (67.9)

African American

28 (20.6)

43 (20.0)

Other

15 (11.0)

26 (12.1)

Body Mass Index (Mean ± SD)

29.6 ± 6.6

28.3 ± 6.8

0.081
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Comorbidities

Diabetes

95 (68.8)

142 (65.14)

0.471

Chronic renal insufficiency

38 (27.5)

48 (22.1)

0.246

End Stage Renal Disease

13 (9.4)

32 (14.7)

0.146

Hypertension

122 (88.4)

190 (87.2)

0.727

Hyperlipidemia

88 (63.8)

126 (57.8)

0.262

Coronary artery disease

57 (41.6)

105 (48.0)

0.199

Congestive heart failure

32 (22.9)

38 (17.4)

0.199

Stroke

21 (15.0)

22 (10.1)

0.159

2 (1.4)

0

0.153

History of cancer

20 (14.3)

35 (16.0)

0.663

Prior endovascular intervention

17 (12.1)

35 (16.0)

0.313

Prior open surgery

15 (10.7)

32 (14.6)

0.286

Serum creatinine

1.6 ± 1.9

1.7 ± 1.9

0.944

Hypercoagulable disorder

Medications
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Aspirin

84 (60.9)

142 (65.7)

0.352

ADP receptor/P2Y12 inhibitor

46 (33.3)

61 (28.0)

0.283

Anticoagulant

22 (16.0)

45 (20.6)

0.269

Statins

87 (63.0)

144 (66.4)

0.523

SD, standard deviation;
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Table II: Procedural characteristics of lower extremity revascularization in compliant and noncompliant patients with CLTI.
Procedures

Non-compliant

Compliant

(N=138)

(N=218)

N(%)

N(%)

Indication

P

0.180
Rest Pain

19 (13.8)

42 (19.3)

Tissue Loss

119 (86.2)

176 (80.7)

Procedure Type

0.003*

Endovascular

128 (92.8)

173 (79.4)

Open

8 (5.8)

37 (17)

Hybrid

2 (1.5)

8 (3.7)

Endovascular treatment

0.430

PTA

61 (47.3)

91 (50.3)

Stent

41 (31.8)

63 (34.8)

Atherectomy

21 (16.3)

18 (9.9)

Atherectomy/Stent

6 (4.7)

9 (5)

Endovascular anatomical location

0.051

Aortoiliac

7 (5.4)

27 (15)

Femoro-popliteal

42 (32.6)

56 (31.1)

Tibial

45 (34.9)

49 (27.2)

Multi-level

35 (27.1)

48 (26.7)
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Open Surgery
Suprainguinal bypass

1 (0.72)

8 (3.7)

Axillary to femoral bypass

1 (100)

4 (50)

Aorta/iliac artery bypass

0

4 (50)

Infrainguinal bypass

8 (5.8)

29 (13.3)

0.024*

Common femoral endarterectomy

3 (2.2)

19 (8.7)

0.013*

PTA, Percutaneous transluminal angioplasty.
*statistically significant

0.085
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Table III: Perioperative outcomes of compliant and non-compliant patients with CLTI
undergoing lower extremity revascularization
Short-term Outcomes (30 days)

Non-Compliant

Compliant

(N=138)

(N=218)

N(%)

N(%)

Hematoma

3 (2.3)

4 (1.9)

1.000

Pseudoaneurysm

2 (1.5)

1 (0.46)

0.561

Bleeding

10 (7.5)

19 (8.8)

0.665

Wound infection

7 (5.3)

19 (8.8)

0.222

Pneumonia

2 (1.5)

1 (0.46)

0.560

Urinary tract infection

1 (0.76)

3 (1.4)

1.000

Arterial Thrombosis

2 (1.5)

2 (0.93)

0.639

Deep venous thrombosis

3 (2.3)

5 (2.3)

1.000

0

1 (0.46)

1.000

8 (6)

11 (5.1)

0.809

Acute/new HD requirement

1 (0.75)

4 (1.85)

0.653

Return to Operating room

14 (10.6)

36 (16.7)

0.118

5 (3.8)

8 (3.7)

1.000

32 (23.2)

58 (26.6)

0.470

2 (1.5)

0

0.146

Stroke
Acute renal failure

Major amputation
Any morbidity
Mortality
HD, hemodialysis

P
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Table IV: Long-term Outcomes of compliant and non-compliant patients with CLTI undergoing
revascularization
Long-term Outcomes

Non-Compliant

Compliant

P

(N=138)

(N=218)

N(%)

N(%)

Follow-up time (mean in years ± SD)

2.8 ± 2.0

2.6 ± 1.6

0.202

Ipsilateral reintervention rate

47 (34.1)

107 (49.1)

0.005*

Number of ipsilateral reinterventions (mean ±

1.6 ± 1.1

2.2 ± 1.8

0.020*

1.1 ± 2.7

1.5 ± 2.0

0.419

Reintervention rate (any leg)

61 (44.2)

133 (61.0)

0.002*

Number of reinterventions (any leg) (mean ±

2.1 ± 1.7

2.7 ± 2.3

0.036*

1.2 ± 2.4

1.8 ± 2.2

0.094

Ipsilateral Major Amputation

16 (11.6)

40 (18.4)

0.088

Mortality

55 (39.9)

74 (33.9)

0.258

SD)
Ipsilateral Reintervention Index.
(Ipsilateral reintervention/year of follow-up)

SD)
Reintervention Index
(All reinterventions/years of follow-up)

*statistically significant
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Table V: Multivariable regression analysis of independent factors associated with ipsilateral
reintervention, major amputation, and mortality:
Variable

Ipsilateral

Major

Mortality

reintervention

Amputation OR

OR [95% CI]

OR [95% CI]

[95% CI]

Former

0.77 [0.45, 1.31]

0.61 [0.30, 1.25]

1.03 [0.59, 1.81]

Current

1.47 [0.78, 2.77]

0.70 [0.31, 1.61]

1.44 [0.72, 2.90]

Age

0.98 [0.96, 1.00]*

0.99 [0.96, 1.02]

1.05 [1.02, 1.07]*

Body Mass Index

0.97 [0.94, 1.01]

1.00 [0.95, 1.05]

0.99 [0.95, 1.03]

Compliance with follow-up

1.82 [1.15, 2.89]*

1.56 [0.81, 3.00]

0.72 [0.44, 1.16]

Diabetes

0.80 [0.49, 1.33]

0.89 [0.44, 1.78]

0.95 [0.63, 1.83]

End stage renal disease

1.29 [0.66, 2.52]

4.16 [1.95, 8.86]*

4.88 [2.38, 10.01]*

Coronary artery disease

1.08 [0.69, 1.70]

1.00 [0.54, 1.85]

0.65 [0.85, 2.22]

Congestive heart failure

1.17 [0.65, 2.11]

0.36 [0.14, 0.95]*

0.65 [0.83, 2.79]

Procedure Type

0.48 [0.27, 0.83]*

2.59 [1.17, 5.77]*

1.38 [0.68, 2.79]

Smoking

(Open/hybrid)
*statistically significant
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